Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Carfilzomib -a Novel Proteasome Inhibitor- for the Prevention of Acute Graft Versus Host Disease

NCT01991301 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT01991301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01991301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Carfilzomib -a Novel Proteasome Inhibitor- for the Prevention of Acute Graft Versus Host Disease
Lead sponsor
Sheba Medical Center
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2014
Completion date
November 30, 2017
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host disease